GlassScriptPhysician profile
Mariusz J Klin
NPI 1457357006
$27,296.19
in general payments reported to CMS, 2019-2025
20 companies · $484 in 2025
The $484 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $325 · 2021: $535 · 2022: $517 · 2023: $421 · 2024: $25K · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $24K · Food and Beverage: $1,735 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $23,765.50 |
| Food and Beverage | $1,735.40 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $23,765.50 | 2024 | Endocapsule Recorder |
| Abbvie INC. | $2,122.22 | 2019-2025 | |
| Gilead Sciences, INC. | $307.54 | 2019-2025 | Epclusa |
| Phathom Pharmaceuticals, INC. | $261.93 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $198.77 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.84 | 2019-2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $97.59 | 2024 | Iqirvo, Bylvay |
| Aimmune Therapeutics, INC. | $94.32 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $71.61 | 2022-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $52.08 | 2024 | Entyvio |
| Daiichi Sankyo INC. | $31.84 | 2019-2025 | Injectafer |
| Redhill Biopharma INC. | $31.52 | 2022 | |
| Organon LLC | $27.57 | 2024 | |
| Lilly USA, LLC | $22.28 | 2025 | Omvoh |
| Pacira Pharmaceuticals Incorporated | $19.73 | 2024 | Exparel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.08 | 2024 | Zeposia |
| Pharmacosmos Therapeutics INC. | $18.77 | 2023 | Monoferric |
| Capsovision, INC. | $17.43 | 2023 | Capsocam Plus |
| Medtronic, INC. | $16.72 | 2022 | |
| Vivus LLC | $5.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariusz Klin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.